Core Viewpoint - Revvity, Inc. (RVTY) is positioned for growth due to its strong product portfolio and focus on artificial intelligence (AI), despite facing challenges from foreign exchange volatility and integration risks [1][8][9] Company Performance - RVTY's shares have increased by 13.4% year to date, outperforming the industry growth of 0.7% and the S&P 500's increase of 20.8% during the same period [2] - The company has a market capitalization of $15.29 billion and projects a growth rate of 7.6% over the next five years [3] - RVTY's earnings have exceeded the Zacks Consensus Estimate in three of the last four quarters, with an average surprise of 5.02% [3] Product Development - The company has introduced several AI-driven solutions, including the PKeye Workflow Monitor and Signals Research Suite, enhancing its product offerings [3][4] - RVTY's software and informatics segment, particularly the Signals Software, has shown rapid growth, with three new SaaS-based solutions launched in the recent quarter [5] - The launch of a next-generation sequencing solution for Newborn Screening is expected to strengthen RVTY's market leadership [6] Financial Outlook - RVTY's diagnostic businesses have remained robust, with the immunodiagnostics franchise growing in the low double-digits [7] - The Zacks Consensus Estimate for third-quarter 2024 revenues is $678.2 million, reflecting a 1.1% increase from the previous year, while the EPS estimate is $1.13, indicating a year-over-year decline of 4.2% [10]

Revvity, Inc. (RVTY) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by its solid second-quarter 2024 performance and focus on artificial intelligence (AI), is expected to contribute further. Headwinds resulting from foreign exchange volatility and integration risks are major downsides. This Zacks Rank #3 (Hold) company's shares have gained 9.1% year to date compared with 0.6% growth of the industry.The S&P 500 has increased 15% during the same t ...

Investors with an interest in Medical Services stocks have likely encountered both Pediatrix Medical Group (MD) and Revvity (RVTY) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work ...

Revenue Details - Revvity operates under two segments: Life Sciences and Diagnostics [1] Financial Performance - Adjusted operating income for Revvity was $112.4 million, reflecting a 12% decrease from the prior-year quarter [2] - Revenues for Revvity totaled $691.7 million, down 2% year over year and 1% organically, missing the Zacks Consensus Estimate by 0.4% [16] - Revenues from the Life Sciences segment were $378 million, up 1.4% year over year, with an organic increase of 3% [8] - Revenues from the Diagnostics segment were $313.8 million, indicating a 6.7% decrease from the year-ago quarter, with a 6% organic decline [23] - Adjusted operating income for the Diagnostics segment was $97.9 million, up 14.9% from the year-ago quarter [24] - Selling, general and administrative expenses totaled $251.7 million, down 5.8% year over year, while research and development expenses were $48.1 million, down 15.9% [17] Cash Position - At the end of Q2 2024, Revvity had cash and cash equivalents of $1.95 billion, an increase from $1.70 billion at the end of the prior quarter [4] - Net cash provided by operating activities was $158.6 million, compared to a net cash used of $135.3 million in the year-ago quarter [18] 2024 Guidance - For 2024, Revvity expects adjusted EPS in the range of $4.70-$4.80 and revenues between $2.77-$2.79 billion, with the Zacks Consensus Estimate for EPS at $4.64 and revenues at $2.80 billion [12] Market Performance - Revvity's shares have gained 3.6% over the past six months, compared to the industry's growth of 6.7% and the S&P 500 Index's increase of 10.9% [19] - Revvity currently holds a Zacks Rank of 4 (Sell) [13]

Key Takeaways Revvity reported second-quarter profit and sales that exceeded estimates on higher demand for its diagnostic products. The medical equipment maker posted a 1.4% year-over-year increase in revenue at its Diagnostics segment, while revenue at its Life Sciences division declined. Revvity raised its full-year adjusted EPS guidance. Revvity (RVTY) shares advanced Monday after the medical equipment maker formerly known as PerkinElmer posted better-than-expected results and boosted its profit guidanc ...

Revvity, Inc. (NYSE:RVTY) Q2 2024 Earnings Conference Call July 29, 2024 8:00 AM ET Company Participants Steve Willoughby - SVP, IR Prahlad Singh - President & CEO Max Krakowiak - SVP & CFO Conference Call Participants Patrick Donnelly - Citi Jack Meehan - Nephron Research Puneet Souda - Leerink Partners Vijay Kumar - Evercore Matt Sykes - Goldman Sachs Dan Brennan - TD Cowen Catherine Schulte - Baird Luke Sergott - Barclays Michael Ryskin - Bank of America Paul Knight - KeyBanc Rachel Vatnsdal - JP Morgan ...

Revvity (RVTY) came out with quarterly earnings of $1.22 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to earnings of $1.21 per share a year ago. These figures are adjusted for nonrecurring items. Over the last four quarters, the company has surpassed consensus EPS estimates three times. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the ear ...

FOR IMMEDIATE RELEASE July 29, 2024 • Revenue of $692 million; (2)% reported growth; (1)% organic growth • GAAP EPS of $0.45; Adjusted EPS from continuing operations of $1.22 • Raises full year 2024 adjusted EPS guidance Adjusted earnings per share from continuing operations for the quarter was $1.22, as compared to $1.21 in the same period a year ago. Adjusted revenue for the quarter was $692 million, as compared to $709 million in the same period a year ago. Adjusted operating income was $199 million, as ...

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). How Have the Numbers Shaped Up for Revvity? Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- ...

This maker of scientific instruments has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 6.48%. With this earnings history in mind, recent estimates have been moving higher for Revvity. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the company is positive, which is a great sign of an earnings beat, especially when you combine this metric with its nice Zacks Rank. ...